T cell metabolic reprogramming and plasticity

Molecular Immunology

Volumn 68, Issue 2, 2015, Pages 507-512

  Slack, Maria ^b,c,d   Wang, Tingting ^a   Wang, Ruoning ^a,b  

^a THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c NATIONWIDE CHILDREN S HOSPITAL   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

Metabolism; Plasticity; Reprogramming; T lymphocytes

Indexed keywords

ACYLCARNITINE; ARGININE; CYSTEINE; GLUTAMIC ACID; GLUTAMINE; GLYCINE; INTERLEUKIN 21; INTERLEUKIN 23; INTERLEUKIN 6; REACTIVE OXYGEN METABOLITE; RETINOID RELATED ORPHAN RECEPTOR GAMMA; STAT3 PROTEIN; TRANSCRIPTION FACTOR FOXP3; TRYPTOPHAN;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ARTICLE; BIOENERGY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL METABOLISM; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM DISEASE; CYTOKINE PRODUCTION; FATTY ACID OXIDATION; IMMUNOREGULATION; LABORATORY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; NONHUMAN; NUCLEAR REPROGRAMMING; NUTRIENT SUPPLY; OXIDATIVE PHOSPHORYLATION; PENTOSE PHOSPHATE CYCLE; PLASTICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION INITIATION; TUMOR MICROENVIRONMENT; ANIMAL; CELL DIFFERENTIATION; CYTOLOGY; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; T LYMPHOCYTE;

ANIMALS; CELL DIFFERENTIATION; HUMANS; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES;

EID: 84949096958     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2015.07.036     Document Type: Article

References (97)

1. Arpaia N., Campbell C., Fan X., Dikiy S., van der Veeken J., deRoos P., et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 2013, 504(7480):451-455.
2. Bensinger S.J., Bradley M.N., Joseph S.B., Zelcer N., Janssen E.M., Hausner M.A., Shih R., Parks J.S., Edwards P.A., Jamieson B.D., Tontonoz P. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell 2008, 134:97-111.
3. Berod L., Friedrich C., Nandan A., et al. De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells. Nat. Med. 2014, 20(11):1327-1333.
4. + T cells to Th1 cells. PLoS One 2014, 9(1):e86257.
5. Blagih J., Coulombe F., Vincent E.E., et al. The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo. Immunity 2015, 42(1):41-54.
6. Boroughs L.K., DeBerardinis R.J. Metabolic pathways promoting cancer cell survival and growth. Nat. Cell Biol. 2015, 17(4):351-359.
7. Bronietzki A.W., Schuster M., Schmitz I. Autophagy in T-cell development, activation and differentiation. Immunol. Cell Biol. 2015, 93(January (1)):25-34.
8. Cairns R.A., Harris I.S., Mak T.W. Regulation of cancer cell metabolism. Nat. Rev. Cancer 2011, 11(2):85-95.
9. Cao Y., Rathmell J.C., Macintyre A.N. Metabolic reprogramming towards aerobic glycolysis correlates with greater proliferative ability and resistance to metabolic inhibition in CD8 versus CD4 T cells. PLoS One 2014, 9(8).
10. Carr E.L., Kelman A., Wu G.S., Gopaul R., Senkevitch E., Aghvanyan A., et al. Glutamine uptake and metabolism are coordinately regulated by ERK/MAPK during T lymphocyte activation. J. Immunol. 2010, 185:1037-1044.
11. + T cells. Eur. J. Immunol. 2008, 38.
12. Chang C.H., Curtis J.D., Maggi L.B., Faubert B., Villarino A.V., O'Sullivan D., et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 2013, 153(June (6)):1239-1251.
13. Chi H. Regulation and function of mTOR signalling in T cell fate decisions. Nat. Rev. Immunol. 2012, 12:325-338.
14. + T cell longevity. Cell 2014, 161(4):750-761.
15. Dang E.V., Barbi J., Yang H.Y., Jinasena D., Yu H., Zheng Y., et al. Control of T(H) 17/T(reg) balance by hypoxia-inducible factor 1. Cell 2011, 146:772-784.
16. Dang C.V. Links between metabolism and cancer. Genes Dev. 2012, 26(May (9)):877-890.
17. DeBerardinis R.J., Cheng T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 2010, 29(January (3)):313-324.
18. Delgoffe G.M., Powell J.D. Sugar, fat, and protein: new insights into what T cells crave. Curr. Opin. Immunol. 2015, 33(April):49-54.
19. Delgoffe G.M., et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat. Immunol. 2011, 12:295-303.
20. Dhup S., Dadhich R.K., Porporato P.E., Sonveaux P. Multiple biological activities of lactic acid in cancer: influences on tumor growth, angiogenesis and metastasis. Curr. Pharm. Des. 2012, 18(10):1319-1330.
21. Donohoe D.R., Garge N., Zhang X., Sun W., O'Connell T.M., Bunger M.K., Bultman S.J. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metab. 2011, 13(5):517-526.
22. Finlay D., Cantrell D.A. Metabolism, migration and memory in cytotoxic T cells. Nat. Rev. Immunol. 2011, 11:109-117.
23. Frauwirth K., Riley J., Harris M., Parry R., Rathmell J., Plas D., et al. The CD28 signaling pathway regulates glucose metabolism. Immunity 2002, 16:769-777.
24. Furusawa Y., Obata Y., Fukuda S., Endo T.A., Nakato G., Takahashi D., et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013, 504(December (7480)):446-450.
25. Gatza E., Wahl D.R., Opipari A.W., Sundberg T.B., Reddy P., Liu C., et al. Manipulating the bioenergetics of alloreactive T cells causes their selective apoptosis and arrests graft-versus-host disease. Sci. Transl. Med. 2011, 3(67):67ra8.
26. Gerriets V.A., Rathmell J.C. Metabolic pathways in T cell fate and function. Trends Immunol. 2012, 33(4):168-173.
27. + T cell subsets and inflammation. J. Clin. Invest. 2015, 125(January (1)):194-207.
28. Ghesquiere B., Wong B.W., Kuchnio A., Carmeliet P. Metabolism of stromal and immune cells in health and disease. Nature 2014, 511:167-176.
29. Gladden L.B. Lactate metabolism: a new paradigm for the third millennium. J. Physiol. 2004, 558(Pt 1):5-30.
30. Grumont R., Lock P., Mollinari M., Shannon F.M., Moore A., Gerondakis S. The mitogen-induced increase in T cell size involves PKC and NFAT activation of Rel/NF-kappaB-dependent c-myc expression. Immunity 2004, 21:19-30.
31. He M.X., McLeod I.X., Jia W., He Y.W. Macroautophagy in T lymphocyte development and function. Front. Immunol. 2012, 3(Feb):22.
32. Hsu P.P., Sabatini D.M. Cancer cell metabolism: Warburg and beyond. Cell 2008, 134(5):703-707.
33. Jacobs S.R., Herman C.E., MacIver N.J., Wofford J.A., Wieman H.L., Hammen J.J., et al. Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways. J. Immunol. 2008, 180:4476-4486.
34. Joyce J.A., Fearon D.T. T cell exclusion, immune privilege, and the tumor microenvironment. Science 2015, 348(6230):74-80.
35. June C.H., Riddell S.R., Schumacher T.N. Adoptive cellular therapy: a race to the finish line. Sci. Transl. Med. 2015, 7:208ps7.
36. Kidani Y., Elsaesser H., Hock M.B., Vergnes L., Williams K.J., Argus J.P., et al. Sterol regulatory element-binding proteins are essential for the metabolic programming of effector T cells and adaptive immunity. Nat. Immunol. 2013, 14:489-499.
37. Lind D.S. Arginine and cancer. J. Nutr. 2004, 134(Suppl. 10):2837S-2841S.
38. Lob S., Konigsrainer A. Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees. Nat. Rev. Cancer 2009, 9(6):445-452.
39. Lochner M., Berod L., Sparwasser T. Fatty acid metabolism in the regulation of T cell function. Trends Immune. 2015, 36(2):81-91.
40. MacIver N.J., Michalek R.D., Rathmell J.C. Metabolic regulation of T lymphocytes. Annu. Rev. Immunol. 2013, 31:259-8310. 1146.
41. Macintyre A.N., Gerriets V.A., Nichols A.G., et al. The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. Cell Metab. 2014, 20(July (1)):61-72.
42. Mascanfroni I.D., Takenaka M.C., Yeste, et al. Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-α. Nat. Med. 2015, 21(6):638-646.
43. Mashimo T., Pichumani K., Vemireddy V., Hatanpaa K.J., Singh D.K., Sirasanagandla S., et al. Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell 2014, 159(December (7)):1603-1614.
44. Mayers J.R., Vander Heiden M.G. Famine versus feast: understanding the metabolism of tumors in vivo. Trends Biochem. Sci. 2015, 40(3):130-140.
45. Merezhinskaya N., Fishbein W.N. Monocarboxylate transporters: past, present, and future. Histol. Histopathol. 2009, 24(2):243-264.
46. Metallo C.M., Vander Heiden M.G. Understanding metabolic regulation and its influence on cell physiology. Mol. Cell. 2013, 49:388-398.
47. + T cell subsets. J. Immunol. 2011, 186:3299-3303.
48. Miller J., Sadelain M. The journey from discoveries in fundamental immunology to cancer immunotherapy. Cancer Cell 2015, 27(4):439-449.
49. Munn D.H., Mellor A.L. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J. Clin. Invest. 2007, 117(5):1147-1154.
50. Nguyen Lt., Ohashi Ps. Clinical blockade of PD1 and LAG3-potential mechanisms of action. Nat. Rev. Immunol. 2015, 15(1):45-56.
51. Nicklin P., Bergman P., Zhang B., Triantafellow E., Wang H., Nyfeler B., et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 2009, 136(February (3)):521-534.
52. + T cells use cell-intrinsic lipolysis to support the metabolic programming necessary for development. Immunity 2014, 41(July (1)):75-88.
53. O'sullivan D., Pearce E.L. Targeting T. cell metabolism for therapy. Trends Immunol. 2015, 36(2):71-80.
54. + T cell immunity through effects on mitochondrial respiration. Science 2015, 348(6238):995-1001.
55. Ostroukhova M., Goplen N., Karim M.Z., Michalec L., Guo L., Liang Q., et al. The role of low-level lactate production in airway inflammation in asthma. Am. J. Physiol. Lung Cell. Mol. Physiol. 2012, 302(3):L300-L307.
56. Parry R.V., Chemnitz J.M., Frauwirth K.A., et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell Biol. 2005, 25(November (21)):9543-9553.
57. Patsoukis N., Bardhan K., Chatterjee P., et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat. Commun. 2015, 26(6):6692.
58. Pearce E.L., Poffenberger M.C., Chang C.H., Jones R.G. Fueling immunity: insights into metabolism and lymphocyte function. Science 2013, 342:1242454.
59. Peter C., Waldmann H., Cobbold S.P. mTOR signalling and metabolic regulation of T cell differentiation. Curr. Opin. Immunol. 2010, 22:655-661.
60. Philp A., Macdonald A.L., Watt P.W. Lactate-a signal coordinating cell and systemic function. J. Exp. Biol. 2005, 208(Pt 24):4561-4575.
61. Pilotte L., Larrieu P., Proc Natl Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Acad. Sci. U. S. A. 2012, 109(7):2497-2502.
62. Pot C., Apetoh L., Awasthi A., Kuchroo V.K. Induction of regulatory Tr1 cells and inhibition of TH17 cells by IL-27. Semin. Immunol. 2011, 23(6):438-445.
63. Psychogios N., Hau D.D., Peng J., Guo A.C., Mandal R., Bouatra S., et al. The human serum metabolome. PLoS One 2011, 6(2):e16957.
64. + T cell formation. eLife 2014, 3:e03706.
65. Restifo N.P., Dudley M.E., Rosenberg S.A. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 2012, 12(March (3)):269-281.
66. Roth S., Droge W. Regulation of interleukin 2 production, interleukin 2 mRNA expression and intracellular glutathione levels in ex vivo derived T lymphocytes by lactate. Eur. J. Immunol. 1991, 21(8):1933-1937.
67. Roth S., Gmunder H., Droge W. Regulation of intracellular glutathione levels and lymphocyte functions by lactate. Cell. Immunol. 1991, 136(1):95-104.
68. Saha A., Aoyama K., Taylor P.A., et al. B Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. Blood 2013, 122(7):3062-3073.
69. Scott A.M., Wolchok J.D., Old L.J. Antibody therapy of cancer. Nat. Rev. Cancer 2012, 12(4):278-287.
70. Sharma P., Allison J.P. The future of immune checkpoint therapy. Science 2015, 348(April (6230)):56-61.
71. Shi L.Z., Wang R., Huang G., Vogel P., Neale G., Green D.R., Chi H. HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J. Exp. Med. 2011, 208:1367-1376.
72. Shime H., Yabu M., Akazawa T., Kodama K., Matsumoto M., Seya T., et al. Tumor-secreted lactic acid promotes IL-23/IL-17 proinflammatory pathway. J. Immunol. 2008, 180(11):7175-7183.
73. Shukla S.K., Gebregiworgis T., Purohit V., Chaika N.V., Gunda V., Radhakrishnan P., et al. Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia. Cancer Metab. 2014, 2(September (1)):18. Erratum in: Cancer Metab. 2014; 2: 22.
74. Siska P.J., Rathmell J.C. T cell metabolic fitness in antitumor immunity. Trends Immunol. 2015, 36(4):257-264.
75. Sommer F., Bischof S., Rollinghoff M., Lohoff M. Demonstration of organic anion transport in T lymphocytes. l-Lactate and fluo-3 are target molecules. J. Immunol. 1994, 153(8):3523-3532.
76. Son H.J., Lee J., Lee S.Y., et al. Metformin attenuates experimental autoimmune arthritis through reciprocal regulation of Th17/Treg balance and osteoclastogenesis. Mediators Inflamm. 2014, 2014:973986. (Epub August 20).
77. Srivastava M.K., Sinha P., Clements V.K., Rodriguez P., Ostrand-Rosenberg Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer 2010, 70(1):6.
78. Topalian S.L., Drake C.G., Pardoll D.M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015, 27(April (4)):450-461.
79. + T lymphocyte responses. Nat. Immunol. 2003, 4(4):361-365.
80. van der Windt G.J., Pearce E.L. Metabolic switching and fuel choice during T-cell differentiation and memory development. Immunol. Rev. 2013, 249:27-42.
81. Wang R., Green D.R. Metabolic reprogramming and metabolic dependency in T cells. Immunol. Rev. 2012, 249:14-26.
82. Wang R., Green D.R. The immune diet: meeting the metabolic demands of lymphocyte activation. F1000. Biol. Rep. 2012, 4:9.
83. Wang R., Green D.R. Metabolic checkpoints in activated T cells. Nat. Immunol. 2012, 13:907-915.
84. Wang R., Dillon Christopher P., Shi Lewis Z., Milasta S., Carter R., Finkelstein D., et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity 2011, 35:871-882.
85. Wang T., Liu G., Wang R. The intercellular metabolic interplay between tumor and immune cells. Front. Immunol. 2014, 5:358.
86. Warburg O. On respiratory impairment in cancer cells. Science 1956, 124:269-270.
87. Weinberg S.E., Sena L.A., Chandel N.S. Mitochondria in the regulation of innate and adaptive immunity. Immunity 2015, 42(3):406-417.
88. Wilson C.B., Rowell E., Sekimata M. Epigenetic control of T-helper-cell differentiation. Nat. Rev. Immunol. 2009, 9(February (2)):91-105.
89. Wise D.R., Thompson C.B. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem. Sci. 2010, 35(August (8)):427-433.
90. Xu Y.F., Létisse F., Absalan F., Lu W., Kuznetsova E., Brown G., et al. Nucleotide degradation and ribose salvage in yeast. Mol. Syst. Biol. 2013, 9(May (14)):665.
91. + T cell survival and memory formation. Nat. Immunol. 2014, 15(December (12)):1152-1161.
92. Yabu M., Shime H., Hara H., Saito T., Matsumoto M., Seya T., et al. IL-23-dependent and -independent enhancement pathways of IL-17A production by lactic acid. Int. Immunol. 2011, 23(1):29-41.
93. Yang K., Shrestha S., Zeng H., et al. T cell exit from quiescence and differentiation into Th2 cells depend on Raptor-mTORC1-mediated metabolic reprogramming. Immunity 2013, 39(6):1043-1056.
94. + T cell metabolism reverse lupus. Sci. Transl. Med. 2015, 7(274):274ra18.
95. Zhang J., Fan J., Venneti S., Cross J.R., Takagi T., Bhinder B., et al. Asparagine plays a critical role in regulating cellular adaptation to glutamine depletion. Mol. Cell. 2014, 56(October (2)):205-218.
96. + T cell lineage differentiation. Immunity 2009, 30(5):646-655.
97. Zois C.E., Favaro E., Harris A.L. Glycogen metabolism in cancer. Biochem. Pharmacol. 2014, 92(November (1)):3-11.